Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice

Ahmed Bettaieb, Samah Chahed, Santana Bachaalany, Stephen M Griffey, Bruce D. Hammock, Fawaz Haj

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Acute pancreatitis (AP) is an inflammatory disease, and is one of the most common gastrointestinal disorders worldwide. Soluble epoxide hydrolase (sEH; encoded by Ephx2) deficiency and pharmacological inhibition have beneficial effects in inflammatory diseases. Ephx2 whole-body deficiency mitigates experimental AP in mice, but the suitability of sEH pharmacological inhibition for treating AP remains to be determined. We investigated the effects of sEH pharmacological inhibition on cerulein- and arginine-induced AP using the selective sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), which was administered before and after induction of pancreatitis. Serum amylase and lipase levels were lower in TPPU-treated mice compared with controls. In addition, circulating levels and pancreatic mRNA of the inflammatory cytokines tumor necrosis factor-α, interleukin Il-1β, and Il-6 were reduced in TPPU-treated mice. Moreover, sEH pharmacological inhibition before and after induction of pancreatitis was associated with decreased cerulein- and arginine-induced nuclear factor-κB inflammatory response, endoplasmic reticulum stress, and cell death. sEH pharmacological inhibition before and after induction of pancreatitis mitigated cerulein- and arginineinduced AP. This work suggests that sEH pharmacological inhibition may be of therapeutic value in acute pancreatitis.

Original languageEnglish (US)
Pages (from-to)281-290
Number of pages10
JournalMolecular Pharmacology
Volume88
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Epoxide Hydrolases
Pancreatitis
Pharmacology
Ceruletide
Arginine
Endoplasmic Reticulum Stress
Amylases
Lipase
Interleukin-1
Urea
Cell Death
Tumor Necrosis Factor-alpha
Cytokines
Messenger RNA

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice. / Bettaieb, Ahmed; Chahed, Samah; Bachaalany, Santana; Griffey, Stephen M; Hammock, Bruce D.; Haj, Fawaz.

In: Molecular Pharmacology, Vol. 88, No. 2, 01.08.2015, p. 281-290.

Research output: Contribution to journalArticle

Bettaieb, Ahmed ; Chahed, Samah ; Bachaalany, Santana ; Griffey, Stephen M ; Hammock, Bruce D. ; Haj, Fawaz. / Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice. In: Molecular Pharmacology. 2015 ; Vol. 88, No. 2. pp. 281-290.
@article{dbe5bf837aa64f2083f1cbe7a976f497,
title = "Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice",
abstract = "Acute pancreatitis (AP) is an inflammatory disease, and is one of the most common gastrointestinal disorders worldwide. Soluble epoxide hydrolase (sEH; encoded by Ephx2) deficiency and pharmacological inhibition have beneficial effects in inflammatory diseases. Ephx2 whole-body deficiency mitigates experimental AP in mice, but the suitability of sEH pharmacological inhibition for treating AP remains to be determined. We investigated the effects of sEH pharmacological inhibition on cerulein- and arginine-induced AP using the selective sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), which was administered before and after induction of pancreatitis. Serum amylase and lipase levels were lower in TPPU-treated mice compared with controls. In addition, circulating levels and pancreatic mRNA of the inflammatory cytokines tumor necrosis factor-α, interleukin Il-1β, and Il-6 were reduced in TPPU-treated mice. Moreover, sEH pharmacological inhibition before and after induction of pancreatitis was associated with decreased cerulein- and arginine-induced nuclear factor-κB inflammatory response, endoplasmic reticulum stress, and cell death. sEH pharmacological inhibition before and after induction of pancreatitis mitigated cerulein- and arginineinduced AP. This work suggests that sEH pharmacological inhibition may be of therapeutic value in acute pancreatitis.",
author = "Ahmed Bettaieb and Samah Chahed and Santana Bachaalany and Griffey, {Stephen M} and Hammock, {Bruce D.} and Fawaz Haj",
year = "2015",
month = "8",
day = "1",
doi = "10.1124/mol.114.097501",
language = "English (US)",
volume = "88",
pages = "281--290",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice

AU - Bettaieb, Ahmed

AU - Chahed, Samah

AU - Bachaalany, Santana

AU - Griffey, Stephen M

AU - Hammock, Bruce D.

AU - Haj, Fawaz

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Acute pancreatitis (AP) is an inflammatory disease, and is one of the most common gastrointestinal disorders worldwide. Soluble epoxide hydrolase (sEH; encoded by Ephx2) deficiency and pharmacological inhibition have beneficial effects in inflammatory diseases. Ephx2 whole-body deficiency mitigates experimental AP in mice, but the suitability of sEH pharmacological inhibition for treating AP remains to be determined. We investigated the effects of sEH pharmacological inhibition on cerulein- and arginine-induced AP using the selective sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), which was administered before and after induction of pancreatitis. Serum amylase and lipase levels were lower in TPPU-treated mice compared with controls. In addition, circulating levels and pancreatic mRNA of the inflammatory cytokines tumor necrosis factor-α, interleukin Il-1β, and Il-6 were reduced in TPPU-treated mice. Moreover, sEH pharmacological inhibition before and after induction of pancreatitis was associated with decreased cerulein- and arginine-induced nuclear factor-κB inflammatory response, endoplasmic reticulum stress, and cell death. sEH pharmacological inhibition before and after induction of pancreatitis mitigated cerulein- and arginineinduced AP. This work suggests that sEH pharmacological inhibition may be of therapeutic value in acute pancreatitis.

AB - Acute pancreatitis (AP) is an inflammatory disease, and is one of the most common gastrointestinal disorders worldwide. Soluble epoxide hydrolase (sEH; encoded by Ephx2) deficiency and pharmacological inhibition have beneficial effects in inflammatory diseases. Ephx2 whole-body deficiency mitigates experimental AP in mice, but the suitability of sEH pharmacological inhibition for treating AP remains to be determined. We investigated the effects of sEH pharmacological inhibition on cerulein- and arginine-induced AP using the selective sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), which was administered before and after induction of pancreatitis. Serum amylase and lipase levels were lower in TPPU-treated mice compared with controls. In addition, circulating levels and pancreatic mRNA of the inflammatory cytokines tumor necrosis factor-α, interleukin Il-1β, and Il-6 were reduced in TPPU-treated mice. Moreover, sEH pharmacological inhibition before and after induction of pancreatitis was associated with decreased cerulein- and arginine-induced nuclear factor-κB inflammatory response, endoplasmic reticulum stress, and cell death. sEH pharmacological inhibition before and after induction of pancreatitis mitigated cerulein- and arginineinduced AP. This work suggests that sEH pharmacological inhibition may be of therapeutic value in acute pancreatitis.

UR - http://www.scopus.com/inward/record.url?scp=84939812796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939812796&partnerID=8YFLogxK

U2 - 10.1124/mol.114.097501

DO - 10.1124/mol.114.097501

M3 - Article

C2 - 25993999

AN - SCOPUS:84939812796

VL - 88

SP - 281

EP - 290

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -